{"product_id":"generic-gilteritinib-gillidx","title":"GILLIDX (Gilteritinib)","description":"Gilteritinib is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.\r\n\r\nGilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.\r\n\r\n\u003cstrong\u003eAcute Myeloid Leukemia\u003c\/strong\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated for treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation\u003c\/li\u003e\r\n \t\u003cli\u003e120 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eResponse may be delayed\u003c\/li\u003e\r\n \t\u003cli\u003eContinue for at least 6 months for a clinical response or until disease progression or unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797948723243,"sku":"RL10202303151000","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-05-265.jpg?v=1787022121","url":"https:\/\/xomeds.com\/products\/generic-gilteritinib-gillidx","provider":"XOMEDS","version":"1.0","type":"link"}